A Network Pharmacology Study of Chinese Medicine QiShenYiQi to Reveal Its Underlying Multi-Compound, Multi-Target, Multi-Pathway Mode of Action

Chinese medicine is a complex system guided by traditional Chinese medicine (TCM) theories, which has proven to be especially effective in treating chronic and complex diseases. However, the underlying modes of action (MOA) are not always systematically investigated. Herein, a systematic study was designed to elucidate the multi-compound, multi-target and multi-pathway MOA of a Chinese medicine, QiShenYiQi (QSYQ), on myocardial infarction. QSYQ is composed of Astragalus membranaceus (Huangqi), Salvia miltiorrhiza (Danshen), Panax notoginseng (Sanqi), and Dalbergia odorifera (Jiangxiang). Male Sprague Dawley rat model of myocardial infarction were administered QSYQ intragastrically for 7 days while the control group was not treated. The differentially expressed genes (DEGs) were identified from myocardial infarction rat model treated with QSYQ, followed by constructing a cardiovascular disease (CVD)-related multilevel compound-target-pathway network connecting main compounds to those DEGs supported by literature evidences and the pathways that are functionally enriched in ArrayTrack. 55 potential targets of QSYQ were identified, of which 14 were confirmed in CVD-related literatures with experimental supporting evidences. Furthermore, three sesquiterpene components of QSYQ, Trans-nerolidol, (3S,6S,7R)-3,7,11-trimethyl-3,6-epoxy-1,10-dodecadien-7-ol and (3S,6R,7R)-3,7,11-trimethyl-3,6-epoxy-1,10-dodecadien-7-ol from Dalbergia odorifera T. Chen, were validated experimentally in this study. Their anti-inflammatory effects and potential targets including extracellular signal-regulated kinase-1/2, peroxisome proliferator-activated receptor-gamma and heme oxygenase-1 were identified. Finally, through a three-level compound-target-pathway network with experimental analysis, our study depicts a complex MOA of QSYQ on myocardial infarction.

[1]  M. Kilgore,et al.  The PPARγ Antagonist T0070907 Suppresses Breast Cancer Cell Proliferation and Motility via Both PPARγ-dependent and -independent Mechanisms , 2011 .

[2]  Huimin Wang,et al.  PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways , 2010, Inflammation Research.

[3]  G. Barber,et al.  Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. , 2011, Current opinion in immunology.

[4]  N. Abraham,et al.  Pharmacological and Clinical Aspects of Heme Oxygenase , 2008, Pharmacological Reviews.

[5]  T. Moon,et al.  The naturally occurring biflavonoid, ochnaflavone, inhibits LPS-induced iNOS expression, which is mediated by ERK1/2 via NF-kappaB regulation, in RAW264.7 cells. , 2006, Archives of biochemistry and biophysics.

[6]  F. Cheung.  TCM: Made in China , 2011, Nature.

[7]  S. Hong,et al.  Inhibitory effect of essential oil from Agastache rugosa against nitric oxide (NO) production induced by inducible nitric oxide synthase (iNOS) over-expression through NF-κB and mitogen-activated protein kinase (MAPK) activation in lipopolysaccharide (LPS)- stimulated RAW264.7 cells , 2012 .

[8]  Harry Martin.  Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. , 2009, Mutation research.

[9]  D. Sabatini,et al.  mTOR signaling at a glance , 2009, Journal of Cell Science.

[10]  Xiang Li,et al.  CHD@ZJU: a knowledgebase providing network-based research platform on coronary heart disease , 2013, Database J. Biol. Databases Curation.

[11]  J. Mcgiff,et al.  Arachidonic acid metabolism. , 1987, Preventive medicine.

[12]  J. Collins,et al.  Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks , 2005, Nature Biotechnology.

[13]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[14]  I. Campbell.  The Clinical Significance of PPAR Gamma Agonism. , 2005, Current molecular medicine.

[15]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[16]  Seong-Jin Kim,et al.  Heme oxygenase-1 mediates the anti-inflammatory effect of mushroom Phellinus linteus in LPS-stimulated RAW264.7 macrophages. , 2006, Journal of ethnopharmacology.

[17]  J. Holder,et al.  PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. , 2000, Trends in pharmacological sciences.

[18]  Patricia J Keely,et al.  Focal adhesion regulation of cell behavior. , 2004, Biochimica et biophysica acta.

[19]  Jean Paul Thiery,et al.  Focal adhesions: Structure and dynamics , 2000, Biology of the cell.

[20]  R. Foresti,et al.  Carbon monoxide‐releasing molecules (CO‐RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages , 2005, British journal of pharmacology.

[21]  B. Humphreys,et al.  Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. , 2010, Seminars in nephrology.

[22]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[23]  K. Maehara,et al.  Apoptosis in relevant clinical situations: contribution of apoptosis in myocardial infarction. , 2000, Cardiovascular research.

[24]  I. Tikkanen,et al.  Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. , 2001, American journal of physiology. Heart and circulatory physiology.

[25]  J. Holder,et al.  PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer , 2000 .

[26]  I. Tsuji,et al.  Increased plasma tissue factor levels in acute myocardial infarction. , 1997, American heart journal.

[27]  S. L. Bridges,et al.  Journal of Neuroinflammation BioMed Central Hypothesis , 2007 .

[28]  R. Hobson,et al.  Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation. , 2004, American journal of physiology. Heart and circulatory physiology.

[29]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[30]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[31]  Andre Terzic,et al.  Chronic Diseases: The Emerging Pandemic , 2011, Clinical and translational science.

[32]  Harry Martin.  Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. , 2009, Mutation research.

[33]  W. Chao.  Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. , 2009, American journal of physiology. Heart and circulatory physiology.

[34]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[35]  Wei Liu,et al.  A Network Study of Chinese Medicine Xuesaitong Injection to Elucidate a Complex Mode of Action with Multicompound, Multitarget, and Multipathway , 2013, Evidence-based complementary and alternative medicine : eCAM.

[36]  Lingyan Yu,et al.  QI-SHEN-YI-QI accelerates angiogenesis after myocardial infarction in rats. , 2010, International journal of cardiology.

[37]  T. Ravikumar,et al.  Vasoactive Hormone Adrenomedullin and Its Binding Protein: Anti-Inflammatory Effects by Up-Regulating Peroxisome Proliferator-Activated Receptor-γ1 , 2007, The Journal of Immunology.

[38]  M. Lazar,et al.  Transcriptional Activation by Peroxisome Proliferator-activated Receptor γ Is Inhibited by Phosphorylation at a Consensus Mitogen-activated Protein Kinase Site* , 1997, The Journal of Biological Chemistry.

[39]  A. Terzic,et al.  Cardiovascular Health: The Global Challenge , 2011, Clinical pharmacology and therapeutics.

[40]  Yiyu Cheng,et al.  Simultaneous Determination of Seven Bioactive Compounds in Chinese Medicine “QI-SHEN-YI-QI” Dropping Pill by LC-UV and LC-ELSD , 2008 .

[41]  John D Lambris,et al.  Interaction between the coagulation and complement system. , 2008, Advances in experimental medicine and biology.

[42]  J. Collins,et al.  Inferring Genetic Networks and Identifying Compound Mode of Action via Expression Profiling , 2003, Science.

[43]  D. Philpott,et al.  Nod-like proteins in immunity, inflammation and disease , 2006, Nature Immunology.

[44]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[45]  S. Blüml,et al.  Expression of Heme Oxygenase-1 in Human Vascular Cells Is Regulated by Peroxisome Proliferator-Activated Receptors , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[46]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[47]  Michael L. Creech,et al.  Integration of biological networks and gene expression data using Cytoscape , 2007, Nature Protocols.

[48]  K. Ahn,et al.  Zuonin B Inhibits Lipopolysaccharide-Induced Inflammation via Downregulation of the ERK1/2 and JNK Pathways in RAW264.7 Macrophages , 2012, Evidence-based complementary and alternative medicine : eCAM.

[49]  G. Núñez,et al.  NOD-like receptors: role in innate immunity and inflammatory disease. , 2009, Annual review of pathology.

[50]  Peter Carmeliet,et al.  Hypoxia and inflammation. , 2011, The New England journal of medicine.

[51]  B. Nilsson,et al.  Complement and coagulation: strangers or partners in crime? , 2007, Trends in immunology.

[52]  Guoyao Wu,et al.  Glutathione metabolism and its implications for health. , 2004, The Journal of nutrition.

[53]  H. Kitano.  Systems Biology: A Brief Overview , 2002, Science.

[54]  S. Hirota,et al.  Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease. , 2009, Recent patents on inflammation & allergy drug discovery.

[55]  B. Finck,et al.  The PPAR regulatory system in cardiac physiology and disease. , 2007, Cardiovascular research.

[56]  Cheng Yiyu,et al.  Identification of major constituents in the traditional Chinese medicine "QI-SHEN-YI-QI" dropping pill by high-performance liquid chromatography coupled with diode array detection-electrospray ionization tandem mass spectrometry. , 2008, Journal of pharmaceutical and biomedical analysis.

[57]  A. Hopkins.  Network pharmacology , 2007, Nature Biotechnology.

[58]  Seong-ho Lee,et al.  Anti-inflammatory activity of patchouli alcohol in RAW264.7 and HT-29 cells. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[59]  Weida Tong,et al.  ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. , 2003, Environmental health perspectives.

[60]  A. Gabrielsen,et al.  The use of network analyses for elucidating mechanisms in cardiovascular disease. , 2010, Molecular bioSystems.

[61]  F. Bach,et al.  Heme oxygenase-1: unleashing the protective properties of heme. , 2003, Trends in immunology.

[62]  G. Bing,et al.  Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt , 2008, Journal of Neuroinflammation.

[63]  W. Wahli,et al.  PPARs at the crossroads of lipid signaling and inflammation , 2012, Trends in Endocrinology & Metabolism.

[64]  M. Pfeffer,et al.  Myocardial Infarct Size and Ventricular Function in Rats , 1979, Circulation research.

[65]  Peiqing Liu,et al.  Cryptotanshinone Suppressed Inflammatory Cytokines Secretion in RAW264.7 Macrophages through Inhibition of the NF-κB and MAPK Signaling Pathways , 2011, Inflammation.

[66]  Wen-yue Jiang,et al.  Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. , 2005, Trends in pharmacological sciences.

[67]  J. V. Vanden Heuvel,et al.  Modulation of PPAR activity via phosphorylation. , 2007, Biochimica et biophysica acta.

[68]  Yi Tao,et al.  Bioactive sesquiterpenes isolated from the essential oil of Dalbergia odorifera T. Chen. , 2010, Fitoterapia.

[69]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[70]  Jianbin Zheng,et al.  Co-administration of Dalbergia odorifera increased bioavailability of Salvia miltiorrhizae in rabbits. , 2007, The American journal of Chinese medicine.

[71]  Hui-Yi Lin,et al.  Inhibition of lipopolysaccharide-induced nitric oxide production by flavonoids in RAW264.7 macrophages involves heme oxygenase-1. , 2003, Biochemical pharmacology.

[72]  M. Goumans,et al.  Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction , 2008, Circulation research.

[73]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[74]  B. Kamińska.  MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. , 2005, Biochimica et biophysica acta.

[75]  P. Fagenholz,et al.  Hypoxia and inflammation. , 2011, The New England journal of medicine.

[76]  Peiying Shi,et al.  Metabolite profiling and pharmacokinetics of herbal compounds following oral administration of a cardiovascular multi-herb medicine (Qishen yiqi pills) in rats. , 2012, Current drug metabolism.

[77]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[78]  T. Resink,et al.  Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) ‐dependent signaling , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  B. Brüne,et al.  PPARγ stabilizes HO-1 mRNA in monocytes/macrophages which affects IFN-β expression. , 2011, Free radical biology & medicine.

[80]  Young-Jae Nam,et al.  The Mitochondrial Death Pathway and Cardiac Myocyte Apoptosis , 2004, Circulation research.